James Noble becomes full-time CEO of Adaptimmune
This article was originally published in Scrip
Adaptimmune, a biotechnology company focused on the use of engineered T cells to treat cancer, has named James Noble full-time CEO – effective 31 March 2014. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as CEO of sister company, Immunocore. He will remain on the Board of Immunocore as a non-executive director. Meanwhile, Dr Jonathan Knowles, currently executive chair of both Adaptimmune and Immunocore, will serve as acting CEO of Immunocore until the company's board appoints a permanent replacement. The move comes as both companies are "at the stage where they each require a full-time CEO to lead further development," said Adaptimmune.